Inclusion Criteria:

          -  Have histologically- or cytologically-confirmed unresectable stage III or stage IV
             melanoma not amenable to local therapy

          -  At least one radiologically measurable lesion as per RECIST 1.1

          -  Have documentation of V600-activating BRAF mutation status or consent to BRAF V600
             mutation testing during the screening period.

          -  ECOG performance status 0 or 1

          -  Ability to ingest oral medications

        Exclusion Criteria:

          -  Has Ocular Melanoma

          -  Has received prior systemic treatment for unresectable or metastatic melanoma (except
             BRAF directed therapy).

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             IDO1 inhibitor or any other antibody or drug specifically targeting checkpoint
             pathways other than anti-CTLA-4 which is permitted in the adjuvant setting.

          -  Has received prior adjuvant therapy, monoclonal antibody or an investigational agent
             or device within 4 weeks or 5 half-lives (whichever is longer)

          -  Has received prior radiotherapy within 2 weeks of therapy.

          -  Is pregnant or breast-feeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of study treatment.

          -  Patients who have active, chronic, or on active treatment for Hep B or Hep C are
             excluded.